ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases.
Ding, C and Xu, J and Li, J (2008) ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Current Opinion in Investigational Drugs, 9 (5). pp. 515-522. ISSN 1472-4472
|PDF - Requires a PDF viewer|
Official URL: http://www.biomedcentral.com/1472-4472/9/515
ABT-874, a fully human mAb that blocks the binding of IL-12 and IL-23 to their shared IL-12 receptor beta1, is currently being developed by Abbott Laboratories for the potential treatment of Crohn's disease and psoriasis. The compound is currently in phase III clinical trials for psoriasis and phase II trials for Crohn's disease. ABT-87 was previously being developed for the potential treatment of multiple sclerosis; however, by May 2007, development for this indication was discontinued.
|Additional Information:||Changhai Ding|
|Deposited By:||Dr Changhai / C Ding|
|Deposited On:||11 Jun 2008 13:56|
|Last Modified:||22 Jun 2009 09:23|
|ePrint Statistics:||View statistics for this ePrint|
Repository Staff Only: item control page